Drug Profile

Elraglusib - Actuate Therapeutics

Alternative Names: 9 ING 41

Latest Information Update: 25 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Northwestern University; University of Illinois at Chicago
Developer Actuate Therapeutics; Incyte Corporation
Class Antineoplastics; Benzofurans; Dioxolanes; Indoles; Pyrroles; Small molecules
Mechanism of Action Glycogen synthase kinase 3 beta inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Glioblastoma; Pancreatic cancer; Soft tissue sarcoma; Neuroblastoma; Adenocarcinoma
New Molecular Entity Yes

Phase II Adenoid cystic carcinoma; Myelofibrosis; Neuroblastoma; Pancreatic cancer; Salivary gland cancer
Phase I/II Cancer
Preclinical Brain cancer
No development reported Chronic lymphocytic leukaemia; Colorectal cancer

22 Sep 2025 Actuate Therapeutics plans phase II trial for Malignant melanoma and Colorectal cancer (Metastatic disease, second-line or greater therapy, In adults) (Actuate Therapeutics pipeline, September 2025)
22 Sep 2025 Actuate Therapeutics plans phase I trial for Solid tumours (Late-stage diseases, second-line or greater therapy, In adults) (Actuate Therapeutics pipeline, September 2025)
22 Sep 2025 Actuate Therapeutics plans phase I trial for Solid tumours and Haematological malignancies (Late-stage diseases, second-line or greater therapy, In Children) (Actuate Therapeutics pipeline, September 2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com